Alkermes plc (NASDAQ: ALKS) Stock Competitors & Peer Comparison
See ALKS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ALKS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALKS | $48.99 | +1.34% | 8.4B | 52.66 | $0.95 | N/A |
| VRTX | $477.10 | -0.95% | 121.1B | 25.35 | $18.82 | N/A |
| REGN | $762.63 | +3.29% | 78.6B | 16.71 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $853.82 | -3.26% | 54.3B | 78.75 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.57 | -3.14% | 42.7B | -2.32 | -$4.15 | N/A |
| RVMD | $187.53 | -2.41% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $316.01 | -1.88% | 33.8B | 70.70 | $4.47 | N/A |
| ALNY | $205.52 | -28.30% | 27.4B | 37.02 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ALKS vs VRTX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while VRTX trades at $477.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas VRTX's P/E ratio is 25.35. In terms of profitability, ALKS's ROE is +0.04%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ALKS is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ALKS vs REGN Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while REGN trades at $762.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas REGN's P/E ratio is 16.71. In terms of profitability, ALKS's ROE is +0.04%, compared to REGN's ROE of +0.18%. Regarding short-term risk, ALKS is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
ALKS vs VRNA Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ALKS's ROE is +0.04%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ALKS is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
ALKS vs ARGX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ARGX trades at $853.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ARGX's P/E ratio is 78.75. In terms of profitability, ALKS's ROE is +0.04%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, ALKS is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
ALKS vs SGEN Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ALKS's ROE is +0.04%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ALKS is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ALKS vs RVMDW Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while RVMDW trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, ALKS's ROE is +0.04%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ALKS is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ALKS vs RVMD Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while RVMD trades at $187.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas RVMD's P/E ratio is -26.52. In terms of profitability, ALKS's ROE is +0.04%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ALKS is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
ALKS vs ONC Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ONC trades at $316.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ONC's P/E ratio is 70.70. In terms of profitability, ALKS's ROE is +0.04%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ALKS is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ALKS vs ALNY Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ALNY trades at $205.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ALNY's P/E ratio is 37.02. In terms of profitability, ALKS's ROE is +0.04%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ALKS is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ALKS vs ROIV Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ROIV trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ROIV's P/E ratio is -34.86. In terms of profitability, ALKS's ROE is +0.04%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ALKS is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
ALKS vs INCY Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while INCY trades at $119.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas INCY's P/E ratio is 16.06. In terms of profitability, ALKS's ROE is +0.04%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ALKS is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
ALKS vs BNTX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas BNTX's P/E ratio is -19.61. In terms of profitability, ALKS's ROE is +0.04%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ALKS is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ALKS vs UTHR Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while UTHR trades at $517.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas UTHR's P/E ratio is 19.10. In terms of profitability, ALKS's ROE is +0.04%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ALKS is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
ALKS vs MRNA Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while MRNA trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas MRNA's P/E ratio is -6.73. In terms of profitability, ALKS's ROE is +0.04%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ALKS is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
ALKS vs INSM Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while INSM trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas INSM's P/E ratio is -17.15. In terms of profitability, ALKS's ROE is +0.04%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ALKS is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ALKS vs BGNE Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ALKS's ROE is +0.04%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ALKS is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ALKS vs DNA-WT Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ALKS's ROE is +0.04%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ALKS is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
ALKS vs GMAB Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas GMAB's P/E ratio is 20.77. In terms of profitability, ALKS's ROE is +0.04%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ALKS is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ALKS vs NBIX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while NBIX trades at $166.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas NBIX's P/E ratio is 24.10. In terms of profitability, ALKS's ROE is +0.04%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ALKS is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ALKS vs JAZZ Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while JAZZ trades at $252.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, ALKS's ROE is +0.04%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ALKS is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ALKS vs BBIO Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while BBIO trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas BBIO's P/E ratio is -21.41. In terms of profitability, ALKS's ROE is +0.04%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ALKS is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ALKS vs ASND Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ASND trades at $243.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ASND's P/E ratio is -100.79. In terms of profitability, ALKS's ROE is +0.04%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ALKS is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ALKS vs EXEL Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while EXEL trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas EXEL's P/E ratio is 15.88. In terms of profitability, ALKS's ROE is +0.04%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ALKS is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ALKS vs KRTX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ALKS's ROE is +0.04%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ALKS is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ALKS vs ARWR Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ARWR trades at $84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ARWR's P/E ratio is -39.37. In terms of profitability, ALKS's ROE is +0.04%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ALKS is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ALKS vs BMRN Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while BMRN trades at $60.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas BMRN's P/E ratio is 28.86. In terms of profitability, ALKS's ROE is +0.04%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ALKS is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ALKS vs TECH Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas TECH's P/E ratio is 37.16. In terms of profitability, ALKS's ROE is +0.04%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ALKS is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ALKS vs RNAM Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ALKS's ROE is +0.04%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ALKS is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ALKS vs AXSM Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while AXSM trades at $217.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas AXSM's P/E ratio is -56.92. In terms of profitability, ALKS's ROE is +0.04%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ALKS is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check AXSM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ALKS vs MDGL Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while MDGL trades at $467.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas MDGL's P/E ratio is -36.51. In terms of profitability, ALKS's ROE is +0.04%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ALKS is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check MDGL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ALKS vs SMMT Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while SMMT trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas SMMT's P/E ratio is -8.14. In terms of profitability, ALKS's ROE is +0.04%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ALKS is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ALKS vs KRYS Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while KRYS trades at $341.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas KRYS's P/E ratio is 45.60. In terms of profitability, ALKS's ROE is +0.04%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ALKS is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ALKS vs HALO Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while HALO trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas HALO's P/E ratio is 17.87. In terms of profitability, ALKS's ROE is +0.04%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ALKS is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ALKS vs CYTK Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while CYTK trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas CYTK's P/E ratio is -13.23. In terms of profitability, ALKS's ROE is +0.04%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ALKS is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ALKS vs RXDX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ALKS's ROE is +0.04%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ALKS is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
ALKS vs ABVX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ABVX trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ABVX's P/E ratio is -65.48. In terms of profitability, ALKS's ROE is +0.04%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ALKS is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ALKS vs NUVL Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ALKS's ROE is +0.04%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ALKS is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ALKS vs CRNX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while CRNX trades at $83.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas CRNX's P/E ratio is -16.28. In terms of profitability, ALKS's ROE is +0.04%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ALKS is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ALKS vs PTGX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while PTGX trades at $136.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas PTGX's P/E ratio is -75.49. In terms of profitability, ALKS's ROE is +0.04%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ALKS is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ALKS vs IMGN Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ALKS's ROE is +0.04%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ALKS is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check IMGN's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ALKS vs IONS Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while IONS trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas IONS's P/E ratio is -30.10. In terms of profitability, ALKS's ROE is +0.04%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ALKS is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ALKS vs PRAX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while PRAX trades at $307.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas PRAX's P/E ratio is -23.02. In terms of profitability, ALKS's ROE is +0.04%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ALKS is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ALKS vs SYRE Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while SYRE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas SYRE's P/E ratio is -47.27. In terms of profitability, ALKS's ROE is +0.04%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ALKS is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check SYRE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ALKS vs KYMR Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while KYMR trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas KYMR's P/E ratio is -29.29. In terms of profitability, ALKS's ROE is +0.04%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ALKS is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check KYMR's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ALKS vs BPMC Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ALKS's ROE is +0.04%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ALKS is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ALKS vs APGE Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while APGE trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas APGE's P/E ratio is -30.97. In terms of profitability, ALKS's ROE is +0.04%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ALKS is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ALKS vs CERE Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas CERE's P/E ratio is -16.47. In terms of profitability, ALKS's ROE is +0.04%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ALKS is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ALKS vs TGTX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while TGTX trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas TGTX's P/E ratio is 17.88. In terms of profitability, ALKS's ROE is +0.04%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ALKS is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check TGTX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ALKS vs IMVT Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while IMVT trades at $38.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas IMVT's P/E ratio is -14.46. In terms of profitability, ALKS's ROE is +0.04%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ALKS is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ALKS vs PCVX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while PCVX trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas PCVX's P/E ratio is -7.86. In terms of profitability, ALKS's ROE is +0.04%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ALKS is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ALKS vs IBRX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas IBRX's P/E ratio is -8.44. In terms of profitability, ALKS's ROE is +0.04%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ALKS is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
ALKS vs MTSR Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ALKS's ROE is +0.04%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ALKS is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
ALKS vs MRUS Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ALKS's ROE is +0.04%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ALKS is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ALKS vs RYTM Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while RYTM trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas RYTM's P/E ratio is -31.71. In terms of profitability, ALKS's ROE is +0.04%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ALKS is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ALKS vs ACLX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ALKS's ROE is +0.04%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ALKS is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ALKS vs COGT Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while COGT trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas COGT's P/E ratio is -18.45. In terms of profitability, ALKS's ROE is +0.04%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ALKS is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ALKS vs RETA Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas RETA's P/E ratio is -66.29. In terms of profitability, ALKS's ROE is +0.04%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ALKS is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ALKS vs MIRM Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while MIRM trades at $105.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas MIRM's P/E ratio is -7.78. In terms of profitability, ALKS's ROE is +0.04%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ALKS is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ALKS vs BLTE Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while BLTE trades at $158.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas BLTE's P/E ratio is -84.82. In terms of profitability, ALKS's ROE is +0.04%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ALKS is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
ALKS vs ERAS Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ERAS trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ERAS's P/E ratio is -19.51. In terms of profitability, ALKS's ROE is +0.04%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ALKS is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
ALKS vs CGON Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while CGON trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas CGON's P/E ratio is -30.55. In terms of profitability, ALKS's ROE is +0.04%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ALKS is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ALKS vs CNTA Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ALKS's ROE is +0.04%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ALKS is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ALKS vs XENE Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while XENE trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas XENE's P/E ratio is -13.33. In terms of profitability, ALKS's ROE is +0.04%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ALKS is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ALKS vs LGND Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while LGND trades at $287.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas LGND's P/E ratio is 34.48. In terms of profitability, ALKS's ROE is +0.04%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ALKS is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ALKS vs SRRK Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while SRRK trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas SRRK's P/E ratio is -13.17. In terms of profitability, ALKS's ROE is +0.04%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ALKS is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check SRRK's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ALKS vs PTCT Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while PTCT trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas PTCT's P/E ratio is -29.19. In terms of profitability, ALKS's ROE is +0.04%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ALKS is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ALKS vs CDTX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ALKS's ROE is +0.04%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ALKS is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ALKS vs ABCM Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ALKS's ROE is +0.04%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ALKS is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ALKS vs ISEE Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ALKS's ROE is +0.04%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ALKS is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ALKS vs APLS Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas APLS's P/E ratio is 38.35. In terms of profitability, ALKS's ROE is +0.04%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ALKS is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ALKS vs TVTX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while TVTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas TVTX's P/E ratio is -254.05. In terms of profitability, ALKS's ROE is +0.04%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ALKS is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ALKS vs TERN Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas TERN's P/E ratio is -51.41. In terms of profitability, ALKS's ROE is +0.04%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ALKS is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ALKS vs DFTX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while DFTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas DFTX's P/E ratio is N/A. In terms of profitability, ALKS's ROE is +0.04%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ALKS is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check DFTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
ALKS vs DYN Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while DYN trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas DYN's P/E ratio is -7.82. In terms of profitability, ALKS's ROE is +0.04%, compared to DYN's ROE of -0.64%. Regarding short-term risk, ALKS is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check DYN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ALKS vs CRSP Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while CRSP trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas CRSP's P/E ratio is -9.39. In terms of profitability, ALKS's ROE is +0.04%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ALKS is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ALKS vs FOLD Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ALKS's ROE is +0.04%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ALKS is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ALKS vs AKRO Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ALKS's ROE is +0.04%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ALKS is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check AKRO's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ALKS vs DNTH Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while DNTH trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas DNTH's P/E ratio is -25.89. In terms of profitability, ALKS's ROE is +0.04%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ALKS is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check DNTH's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ALKS vs ALPN Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ALKS's ROE is +0.04%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ALKS is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
ALKS vs ACAD Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ACAD trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ACAD's P/E ratio is 12.68. In terms of profitability, ALKS's ROE is +0.04%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ALKS is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ALKS vs CAI Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while CAI trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas CAI's P/E ratio is -86.19. In terms of profitability, ALKS's ROE is +0.04%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ALKS is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
ALKS vs MANE Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas MANE's P/E ratio is -33.36. In terms of profitability, ALKS's ROE is +0.04%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ALKS is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
ALKS vs OPT Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas OPT's P/E ratio is -1.52. In terms of profitability, ALKS's ROE is +0.04%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ALKS is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ALKS vs PRTC Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ALKS's ROE is +0.04%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ALKS is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check PRTC's competition here
Celcuity Inc. (NASDAQ: CELC)
ALKS vs CELC Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while CELC trades at $86.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas CELC's P/E ratio is -22.15. In terms of profitability, ALKS's ROE is +0.04%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ALKS is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ALKS vs EWTX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while EWTX trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas EWTX's P/E ratio is -23.15. In terms of profitability, ALKS's ROE is +0.04%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ALKS is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ALKS vs MRTX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ALKS's ROE is +0.04%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ALKS is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
ALKS vs ELVN Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ELVN trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ELVN's P/E ratio is -32.82. In terms of profitability, ALKS's ROE is +0.04%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ALKS is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ALKS vs CPRX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ALKS's ROE is +0.04%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ALKS is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ALKS vs RYZB Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ALKS's ROE is +0.04%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ALKS is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ALKS vs CBAY Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ALKS's ROE is +0.04%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ALKS is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
ALKS vs VKTX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while VKTX trades at $31.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas VKTX's P/E ratio is -7.67. In terms of profitability, ALKS's ROE is +0.04%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, ALKS is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
ALKS vs DNLI Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas DNLI's P/E ratio is -7.99. In terms of profitability, ALKS's ROE is +0.04%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ALKS is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ALKS vs ORKA Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ORKA trades at $96.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ORKA's P/E ratio is -49.75. In terms of profitability, ALKS's ROE is +0.04%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, ALKS is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ORKA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ALKS vs ADPT Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ADPT trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ADPT's P/E ratio is -41.80. In terms of profitability, ALKS's ROE is +0.04%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, ALKS is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ADPT's competition here
Alumis Inc. (NASDAQ: ALMS)
ALKS vs ALMS Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ALMS trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ALMS's P/E ratio is -7.39. In terms of profitability, ALKS's ROE is +0.04%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, ALKS is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ALMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
ALKS vs RCUS Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while RCUS trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas RCUS's P/E ratio is -8.66. In terms of profitability, ALKS's ROE is +0.04%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, ALKS is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
ALKS vs SWTX Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ALKS's ROE is +0.04%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ALKS is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ALKS.Check SWTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
ALKS vs ARQT Comparison August 2026
Alkermes plc (NASDAQ: ALKS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALKS stands at 8.4B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, ALKS is priced at $48.99 on the NASDAQ, while ARQT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALKS currently has a P/E ratio of 52.66, whereas ARQT's P/E ratio is -933.00. In terms of profitability, ALKS's ROE is +0.04%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, ALKS is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for ALKS.Check ARQT's competition here